Mineralys Therapeutics Inc. Common Stock (MLYS) Insider Trading
- $58,305,546.00
- $15,528,685.73
- Aug. 13, 2025
- Jon Congleton
| Trader Name | Date | Title | Amount | Price | Type | Total Value |
|---|---|---|---|---|---|---|
| Aug. 13, 2025 | Insider | 11,365 | $12.93 | Sell | $146,949.45 | |
| July 30, 2025 | CFO | 59,925 | $14.76 | Sell | $884,493.00 | |
| July 29, 2025 | CFO | 807 | $14.00 | Sell | $11,298.00 | |
| July 28, 2025 | CFO | 12,946 | $14.04 | Sell | $181,761.84 | |
| July 14, 2025 | Insider | 11,366 | $14.59 | Sell | $165,829.94 | |
| July 11, 2025 | CFO | 10,758 | $14.45 | Sell | $155,453.10 | |
| July 11, 2025 | CEO | 15,884 | $14.51 | Sell | $230,476.84 | |
| May 14, 2025 | Insider | 11,366 | $15.29 | Sell | $173,786.14 | |
| April 14, 2025 | Insider | 11,366 | $14.53 | Sell | $165,147.98 | |
| April 11, 2025 | CFO | 10,757 | $12.06 | Sell | $129,729.42 | |
| April 11, 2025 | CEO | 15,319 | $12.19 | Sell | $186,738.61 | |
| April 1, 2025 | Insider | 55,771 | $15.76 | Sell | $878,950.96 | |
| March 13, 2025 | Major Shareholder | 600,000 | $13.50 | Buy | $8,100,000.00 | |
| March 13, 2025 | Director | 1,296,296 | $13.50 | Buy | $17,499,996.00 | |
| Jan. 13, 2025 | CFO | 10,757 | $9.10 | Sell | $97,888.70 | |
| Jan. 13, 2025 | CEO | 18,333 | $9.06 | Sell | $166,096.98 | |
| Nov. 6, 2024 | Insider | 25,482 | $15.03 | Sell | $382,994.46 | |
| Oct. 11, 2024 | CFO | 10,757 | $13.57 | Sell | $145,972.49 | |
| Oct. 11, 2024 | CEO | 15,271 | $13.52 | Sell | $206,463.92 | |
| July 24, 2024 | Director | 550,000 | $13.05 | Sell | $7,177,500.00 | |
| July 16, 2024 | Insider | 525 | $15.00 | Sell | $7,875.00 | |
| July 11, 2024 | CEO | 15,746 | $13.34 | Sell | $210,051.64 | |
| July 11, 2024 | CFO | 10,757 | $13.14 | Sell | $141,346.98 | |
| June 14, 2024 | CEO | 16,229 | $12.52 | Sell | $203,187.08 | |
| June 12, 2024 | CEO | 16,607 | $12.77 | Sell | $212,071.39 | |
| June 11, 2024 | CFO | 96,815 | $12.94 | Sell | $1,252,786.10 | |
| May 9, 2024 | Insider | 100 | $15.00 | Sell | $1,500.00 | |
| Feb. 12, 2024 | Major Shareholder | 555,555 | $13.50 | Buy | $7,499,992.50 | |
| Nov. 22, 2023 | CEO | 4,250 | $5.97 | Buy | $25,372.50 | |
| Sept. 6, 2023 | CEO | 2,250 | $12.08 | Buy | $27,180.00 | |
| Aug. 17, 2023 | CEO | 2,250 | $12.10 | Buy | $27,225.00 | |
| Aug. 11, 2023 | CEO | 2,000 | $12.89 | Buy | $25,780.00 | |
| Aug. 11, 2023 | insider | 157,091 | $12.81 | Sell | $2,012,335.71 | |
| Feb. 14, 2023 | Major Shareholder | 312,500 | $16.00 | Buy | $5,000,000.00 | |
| Feb. 14, 2023 | Director | 1,250,000 | $16.00 | Buy | $20,000,000.00 | |
| Feb. 14, 2023 | CFO | 6,250 | $16.00 | Buy | $100,000.00 |
Insiders are both buying and selling Mineralys Therapeutics Inc. Common Stock stock.
The insider traders at Mineralys Therapeutics Inc. Common Stock are: Jon Congleton, Adam Scott Levy, David Malcom Rodman, Ra Capital Management, L.P., Samsara Biocapital Gp, Llc, Hbm Healthcare Investments (Ca, and Brian Taylor Slingsby
The most active insider trader at Mineralys Therapeutics Inc. Common Stock is Jon Congleton with 11 trades.
Brian Taylor Slingsby has sold the most Mineralys Therapeutics Inc. Common Stock stock with a total value of $14,355,000.00.
Ra Capital Management, L.P. has bought the most Mineralys Therapeutics Inc. Common Stock stock with a total value of $54,999,992.00.
The most recent insider trade for Mineralys Therapeutics Inc. Common Stock was on Aug. 13, 2025.
The single biggest insider buy for Mineralys Therapeutics Inc. Common Stock was from Ra Capital Management, L.P. with a total value of $20,000,000.00 on Feb. 14, 2023.
The single biggest insider sell for Mineralys Therapeutics Inc. Common Stock was from Brian Taylor Slingsby with a total value of $7,177,500.00 on July 24, 2024.